Nautilus Biotechnology Inc (NASDAQ: NAUT) kicked off on Monday, up 39.10% from the previous trading day, before settling in for the closing price of $1.33. Over the past 52 weeks, NAUT has traded in a range of $0.62-$2.92.
A company in the Healthcare sector has dropped its sales by -4.55% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 6.25%. With a float of $59.68 million, this company’s outstanding shares have now reached $126.31 million.
Nautilus Biotechnology Inc (NAUT) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Nautilus Biotechnology Inc is 52.75%, while institutional ownership is 27.21%. The most recent insider transaction that took place on Sep 05 ’25, was worth 78,544. In this transaction CEO, President, and Secretary of this company bought 116,500 shares at a rate of $0.67, taking the stock ownership to the 10,258,221 shares. Before that another transaction happened on Sep 08 ’25, when Company’s CEO, President, and Secretary bought 83,500 for $0.68, making the entire transaction worth $57,031. This insider now owns 10,341,721 shares in total.
Nautilus Biotechnology Inc (NAUT) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.14 earnings per share (EPS), higher than consensus estimate (set at -0.16) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 6.25% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.75% during the next five years compared to -4.55% drop over the previous five years of trading.
Nautilus Biotechnology Inc (NASDAQ: NAUT) Trading Performance Indicators
Take a look at Nautilus Biotechnology Inc’s (NAUT) current performance indicators. Last quarter, stock had a quick ratio of 14.95.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.50, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.61 in one year’s time.
Technical Analysis of Nautilus Biotechnology Inc (NAUT)
Let’s dig in a bit further. During the last 5-days, its volume was 1.15 million. That was better than the volume of 0.29 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 67.83%.
During the past 100 days, Nautilus Biotechnology Inc’s (NAUT) raw stochastic average was set at 98.40%, which indicates a significant increase from 97.83% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.2395 in the past 14 days, which was higher than the 0.0793 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.9182, while its 200-day Moving Average is $0.9601. However, in the short run, Nautilus Biotechnology Inc’s stock first resistance to watch stands at $2.0367. Second resistance stands at $2.2233. The third major resistance level sits at $2.5767. If the price goes on to break the first support level at $1.4967, it is likely to go to the next support level at $1.1433. Assuming the price breaks the second support level, the third support level stands at $0.9567.
Nautilus Biotechnology Inc (NASDAQ: NAUT) Key Stats
The company with the Market Capitalisation of 233.67 million has total of 126,305K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -70,780 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -15,030 K.
